Hantz Financial Services Inc. Raises Position in Pfizer Inc. (NYSE:PFE)

Hantz Financial Services Inc. lifted its stake in Pfizer Inc. (NYSE:PFE) by 34.5% in the 4th quarter, HoldingsChannel reports. The firm owned 514,184 shares of the biopharmaceutical company’s stock after acquiring an additional 131,760 shares during the period. Hantz Financial Services Inc.’s holdings in Pfizer were worth $13,641,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of PFE. Foster Victor Wealth Advisors LLC grew its holdings in Pfizer by 24.9% during the fourth quarter. Foster Victor Wealth Advisors LLC now owns 564,035 shares of the biopharmaceutical company’s stock valued at $14,834,000 after purchasing an additional 112,616 shares during the period. Robeco Institutional Asset Management B.V. increased its holdings in Pfizer by 41.8% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 6,377,817 shares of the biopharmaceutical company’s stock worth $169,203,000 after acquiring an additional 1,879,504 shares in the last quarter. Asset Dedication LLC raised its stake in Pfizer by 107.4% during the 4th quarter. Asset Dedication LLC now owns 26,833 shares of the biopharmaceutical company’s stock worth $712,000 after acquiring an additional 13,896 shares during the period. BSW Wealth Partners lifted its holdings in Pfizer by 2.1% during the fourth quarter. BSW Wealth Partners now owns 52,935 shares of the biopharmaceutical company’s stock valued at $1,404,000 after purchasing an additional 1,111 shares in the last quarter. Finally, Patriot Financial Group Insurance Agency LLC boosted its position in shares of Pfizer by 1.0% in the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company’s stock worth $1,027,000 after purchasing an additional 391 shares during the period. 68.36% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

PFE has been the topic of several recent analyst reports. UBS Group decreased their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. Sanford C. Bernstein assumed coverage on Pfizer in a research report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective on the stock. Citigroup cut their target price on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday. Bank of America reissued a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. Finally, Truist Financial cut their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Pfizer has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Trading Down 0.3 %

Shares of PFE stock opened at $26.79 on Wednesday. The company has a market cap of $151.79 billion, a PE ratio of 36.20, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock’s 50 day simple moving average is $26.18 and its two-hundred day simple moving average is $27.91. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. The business had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business’s revenue was up 31.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.17) earnings per share. Research analysts predict that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.42%. This is an increase from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. Pfizer’s dividend payout ratio is presently 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.